Assessment of Duration of Staying Free from Acquiring Rehappening Opportunistic Infections among Pre-ART People Living with HIV/AIDS between 2008 and 2013
Table 3
The cumulative incidence of diagnosing OI, Kaplan Meier estimation of median duration of not acquiring OI recurrence and cox proportional hazard model of the association between characteristics and OI recurrence among PLWHA in Debre Markos town between 2007 and 2013.
Variables
Diagnosis of recurrence OI
Median KMS
CHR (95% CI)
AHR (95% CI)
Yes (%)
No (%)
Marital status
Married
101 (39.3)
29 (34.5)
60
1
1
Single
68 (26.5)
11 (13.1)
46
1.65 (1.21–2.26)
1.19 (0.72–1.96)
Divorced
60 (23.3)
32 (38.1)
64
1.02 (0.74–1.41)
0.57 (0.33–0.99)
Widowed
28 (10.9)
12 (14.3)
42
1.69 (1.10–2.59)
1.64 (0.79–3.40)
Educational status
Not educated
110 (42.8)
43 (51.2)
55
1
1
Grades 1–8
82 (31.9)
16 (19)
41
1.06 (0.79–1.41)
1.17 (0.70–1.94)
Grades 9–12
44 (17.1)
14 (16.7)
55
0.84 (0.59–1.19)
1.38 (0.71–2.68)
Above grade 12
21 (8.2)
11 (13.1)
67
0.49 (0.30–0.80)
1.55 (0.69–3.47)
Occupational status
Unemployed
221 (86)
70 (83.3)
53
1
1
Employed
36 (14)
14 (16.7)
76
0.48 (0.33–0.69)
0.34 (0.16–0.71)
Functional statusB.
Working
206 (80.2)
77 (91.7)
60
1
1
Ambulatory/bed-ridden
51 (19.8)
7 (8.3)
32
1.7 (1.25–2.32)
1.59 (0.81–3.12)
Functional statusF.
Working
215 (83.7)
82 (97.6)
60
1
1
Ambulatory/bed-ridden
42 (16.3)
2 (2.4)
37
1.65 (1.17–2.31)
0.97 (0.52–1.81)
Number of OIs treated at base line
1
203 (79)
62 (73.8)
59
1
1
≥2
54 (21)
22 (26.2)
44
1.38 (1.01–1.87)
1.19 (0.69–2.07)
Prophylaxis adherenceB.
Good
170 (91.4)
55 (94.8)
64
1
1
Fair
6 (3.2)
0 (0)
43
2.69 (1.19–6.13)
14.92 (1.03–215)
Poor
10 (5.4)
3 (5.2)
23
1.76 (0.92–3.35)
5.96 (1.21–29.41)
Prophylaxis adherenceF.
Good
173 (88.3)
58 (98.3)
64
1
1
Fair
9 (4.6)
0 (0)
55
1.06 (0.54–2.08)
5.39 (1.77–16.36)
Poor
14 (7.1)
1 (1.7)
22
2.2 (1.27–3.82)
5.79 (1.86–17.98)
Prophylaxis exposureB.
No
71 (27.6)
26 (31)
37
1
1
Yes
186 (72.4)
58 (69)
63
0.64 (0.49–0.85)
0.31 (0.19–0.49)
CD4 count (cells/μL)F.
≤100
4 (2.2)
1 (1.4)
17
1
1
101–199
19 (10.6)
3 (4.2)
60
0.19 (0.06–0.58)
0.12 (0.029–0.49)
200–350
50 (27.8)
27 (37.5)
69
0.14 (0.048–0.39)
0.21 (0.057–0.79)
351–499
58 (32.2)
24 (33.3)
66
0.17 (0.058–0.47)
0.16 (0.045–0.59)
≥500
49 (27.2)
17 (23.6)
70
0.13 (0.046–0.38)
0.17 (0.46–0.62)
Hemoglobin value (g/dL)B.
<10
61 (31.1)
5 (16.7)
26
1
1
≥10
135 (68.9)
25 (83.3)
53
0.55 (0.40–0.75)
0.49 (0.25–0.97)
Body mass index (kg/m2)F.
≤18.4
122 (47.7)
36 (42.9)
46
1
1
18.5–22.9
103 (40.2)
35 (41.7)
54
0.93 (0.71–1.21)
0.89 (0.54–1.46)
≥23
31 (12.1)
13 (15.5)
69
0.54 (0.37–0.79)
0.61 (0.33–1.14)
Herpes Zoster diagnosisB.
No
202 (78.6)
73 (86.9)
55
1
1
Yes
55 (21.4)
11 (13.1)
48
1.38 (1.02–1.86)
1.18 (0.65–2.13)
Wasting syndrome diagnosisB.
No
247 (96.1)
84 (100)
55
1
1
Yes
10 (3.9)
0 (0)
23
2.39 (1.21–4.34)
1.29 (0.36–4.71)
BBase line value.
FFollow-up value. KMS: Kaplan Meier survival in weeks. CHR: crude hazard rate. AHR: Adjusted hazard rate.
